Animalcare Group (ANCR)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

246.00p
   
  • Change Today:
    -3.00p
  • 52 Week High: 284.00p
  • 52 Week Low: 166.40p
  • Currency: UK Pounds
  • Shares Issued: 60.37m
  • Volume: 20,420
  • Market Cap: £148.52m

Animalcare enters collaboration with Dutch firm Orthros

By Josh White

Date: Thursday 24 Mar 2022

LONDON (ShareCast) - (Sharecast News) - Animalcare Group has entered into two early-stage agreements with Netherlands-based Orthros Medical, it announced on Thursday, focussed on the research and early development of 'VHH' antibodies.
The AIM-traded firm said under the collaboration, it had secured a global exclusive licence from Orthros for two preclinical VHH candidates, initially addressing osteoarthritis in dogs.

Additionally, it was entering into a research and development deal with Orthros Medical with the objective of adding further projects to the licence agreement.

Under the terms of the deal, Animalcare would make upfront payments to Orthros of €0.5m (£0.42m), and would fund some early research activities as part of the collaboration.

As the two licensed candidates progressed, Orthros could receive development, regulatory and commercial milestone payments up to a total of €11m, as well as single-digit royalties on net sales of the products.

The payments were expected to be paid out of the group's operating cash flow.

Animalcare said the licensed candidates would be developed as mono and combination therapy for local application in osteoarthritic joints to enable pain relief and, potentially, disease modification.

The candidate profiles were complementary to 'Daxocox', its existing COX-2 inhibitor approved for the treatment of osteoarthritis-related pain in dogs.

"This partnership represents a key building block in our long-term growth strategy," said chief executive officer Jenny Winter.

"We are keen to expand our early-stage pipeline by seeking out innovative technologies to meet evolving customer needs in a fast-growing, competitive market.

"Working with Orthros Medical, we have an exciting opportunity to build our future pain and osteoarthritis portfolio while exploring further potential of Orthros Medical's VHH technology in animals."

At 1422 GMT, shares in Animalcare Group were up 0.63% at 337.12p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

ANCR Market Data

Currency UK Pounds
Share Price 246.00p
Change Today -3.00p
% Change -1.20 %
52 Week High 284.00p
52 Week Low 166.40p
Volume 20,420
Shares Issued 60.37m
Market Cap £148.52m

ANCR Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
88.5% below the market average88.5% below the market average88.5% below the market average88.5% below the market average88.5% below the market average
76% below the sector average76% below the sector average76% below the sector average76% below the sector average76% below the sector average
Price Trend
63.61% above the market average63.61% above the market average63.61% above the market average63.61% above the market average63.61% above the market average
87.76% above the sector average87.76% above the sector average87.76% above the sector average87.76% above the sector average87.76% above the sector average
Income
78.08% below the market average78.08% below the market average78.08% below the market average78.08% below the market average78.08% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
16.87% below the market average16.87% below the market average16.87% below the market average16.87% below the market average16.87% below the market average
23.53% below the sector average23.53% below the sector average23.53% below the sector average23.53% below the sector average23.53% below the sector average

What The Brokers Say

Strong Buy 0
Buy 2
Neutral 0
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

ANCR Dividends

  Latest Previous
  Interim Final
Ex-Div 17-Oct-24 20-Jun-24
Paid 15-Nov-24 19-Jul-24
Amount 2.00p 3.00p

Trades for 21-Nov-2024

Time Volume / Share Price
14:21 100 @ 244.00p
14:19 13 @ 244.00p
13:36 3,000 @ 248.00p
13:12 397 @ 247.90p
11:36 405 @ 246.90p

ANCR Key Personnel

CFO Chris Brewster
CEO Jenny Winter

Top of Page